ES2191031T3 - Proteinas intracelulares de enlace (pil) y sus utilizaciones. - Google Patents

Proteinas intracelulares de enlace (pil) y sus utilizaciones.

Info

Publication number
ES2191031T3
ES2191031T3 ES94919711T ES94919711T ES2191031T3 ES 2191031 T3 ES2191031 T3 ES 2191031T3 ES 94919711 T ES94919711 T ES 94919711T ES 94919711 T ES94919711 T ES 94919711T ES 2191031 T3 ES2191031 T3 ES 2191031T3
Authority
ES
Spain
Prior art keywords
pct
date dec
sec
nucleic acid
pil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94919711T
Other languages
English (en)
Inventor
Fabien Schweighoffer
Bruno Tocque
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Application granted granted Critical
Publication of ES2191031T3 publication Critical patent/ES2191031T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1072—Regulatory proteins, e.g. tat, rev, vpt
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A SECUENCIAS NUCLEICAS, LOS VECTORES QUE LOS CONTIENEN Y SUS UTILIZACIONES TERAPEUTICAS, PARTICULARMENTE EN TERAPIA GENICA. MAS PARTICULARMENTE, LA PRESENTE INVENCION SE REFIERE A SECUENCIA NUCLEICAS QUE COMPRENDE UN GEN QUE CODIFICA UNA PROTEINA INTRACELULAR DE ENLACE (PIL), Y SU UTILIZACION EN TERAPIA GENICA, EVENTUALMENTE INCORPORADAS A VECTORES DE EXPRESION APROPIADOS.
ES94919711T 1993-06-16 1994-06-15 Proteinas intracelulares de enlace (pil) y sus utilizaciones. Expired - Lifetime ES2191031T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9307241A FR2706486B1 (fr) 1993-06-16 1993-06-16 Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques.

Publications (1)

Publication Number Publication Date
ES2191031T3 true ES2191031T3 (es) 2003-09-01

Family

ID=9448183

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94919711T Expired - Lifetime ES2191031T3 (es) 1993-06-16 1994-06-15 Proteinas intracelulares de enlace (pil) y sus utilizaciones.

Country Status (24)

Country Link
US (1) US6159947A (es)
EP (1) EP0703980B1 (es)
JP (1) JP4384260B2 (es)
KR (1) KR100342233B1 (es)
CN (1) CN1076052C (es)
AT (1) ATE231916T1 (es)
AU (1) AU7076394A (es)
BR (1) BR9407512A (es)
CA (1) CA2165458C (es)
CZ (1) CZ289039B6 (es)
DE (1) DE69432075T2 (es)
DK (1) DK0703980T3 (es)
ES (1) ES2191031T3 (es)
FI (1) FI120311B (es)
FR (1) FR2706486B1 (es)
HU (1) HU219138B (es)
NO (1) NO319466B1 (es)
NZ (1) NZ268038A (es)
PL (1) PL180760B1 (es)
RU (1) RU2218400C2 (es)
SK (1) SK285169B6 (es)
UA (1) UA46709C2 (es)
WO (1) WO1994029446A2 (es)
ZA (1) ZA944303B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790633B1 (en) * 1990-04-18 2004-09-14 Michael S. Brown Method of inhibiting a farnesyl transferase enzyme
US8003342B1 (en) 1990-04-18 2011-08-23 Board Of Regents, The University Of Texas System Method for identifying farnesyl transferase inhibitors
FR2724320B1 (fr) * 1994-09-13 1996-12-20 Transgene Sa Nouvel implant pour le traitement des maladies acquises
US5518042A (en) * 1994-09-16 1996-05-21 Huyck Licensco, Inc. Papermaker's forming fabric with additional cross machine direction locator and fiber supporting yarns
FR2738151B1 (fr) * 1995-09-04 1997-09-26 Rhone Poulenc Rorer Sa Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers
DE69732789T2 (de) 1996-12-06 2005-08-11 Aventis Pharmaceuticals Inc. Von humanem lipase-ähnlichem gen kodierte polypeptide, sowie zusammensetzungen und methoden
US7008776B1 (en) * 1996-12-06 2006-03-07 Aventis Pharmaceuticals Inc. Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
FR2758569B1 (fr) * 1997-01-20 1999-04-02 Centre Nat Rech Scient Materiel biologique pour le traitement d'un mammifere par transfert de gene d'anticorps et composition pharmaceutique le concernant
WO2000050089A2 (en) * 1999-02-26 2000-08-31 Mindset Biopharmaceuticals (Usa) Ltd. Regulation of the stability of recombinant proteins and antiboodies
FR2794771B1 (fr) 1999-06-11 2001-08-10 Aventis Pharma Sa Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
IL151987A0 (en) 2000-03-31 2003-04-10 Aventis Pharma Inc Nuclear factor kb inducing factor
GB0018307D0 (en) 2000-07-26 2000-09-13 Aventis Pharm Prod Inc Polypeptides
US20030104402A1 (en) * 2001-01-23 2003-06-05 University Of Rochester Methods of producing or identifying intrabodies in eukaryotic cells
US9328142B2 (en) 2011-05-25 2016-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lipopeptide inhibitors of RAS oncoproteins
KR101602876B1 (ko) 2014-07-22 2016-03-11 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용
KR101602870B1 (ko) 2014-07-22 2016-03-21 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용
KR102023289B1 (ko) * 2014-10-23 2019-09-19 싱 몰레큘러 메디신, 엘엘씨 세포내 항원에 대해 지향된 단일 도메인 항체
US20180072815A1 (en) 2014-10-23 2018-03-15 Singh Biotechnology, Llc Single Domain Antibodies Directed Against Intracellular Antigens
TWI746473B (zh) 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 針對細胞內抗原之單域抗體
US11155641B2 (en) 2016-05-27 2021-10-26 Orum Therapeutics Inc. Cytosol-penetrating antibody and use thereof
WO2019244086A1 (en) 2018-06-21 2019-12-26 Orum Therapeutics Inc. Cell/tissue-specific cell-penetrating antibodies
CN110981943B (zh) * 2019-12-02 2021-08-03 清华大学 多肽及其在制备药物中的用途和药物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3915952A1 (de) * 1989-05-12 1990-12-06 Peter Werner Wirkstoff/medikament/biotechnologisches verfahren zur behandlung von erkrankungen, die mit exo- oder endogenen intrazellulaeren proteinen (onkogene etc.) assoziert sind
AU8628291A (en) * 1990-09-25 1992-04-15 University Of Connecticut, The Prolonging expression of polynucleotides introduced into a cell
CA2072249C (en) * 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
DK0610286T3 (da) * 1991-09-30 2000-07-17 Us Health Rekombinante immunotoxiner
AU668374B2 (en) * 1991-12-10 1996-05-02 Dana-Farber Cancer Institute Reactive neutralizing human anti-GP120 recombinant antibody, DNA coding the same and use thereof
DE69334095T2 (de) * 1992-07-17 2007-04-12 Dana-Farber Cancer Institute, Boston Verfahren zur intrazellulären Bindung von zielgerichteten Molekülen

Also Published As

Publication number Publication date
HU9503615D0 (en) 1996-02-28
PL180760B1 (pl) 2001-04-30
SK285169B6 (sk) 2006-07-07
WO1994029446A3 (fr) 1995-02-02
FI120311B (fi) 2009-09-15
UA46709C2 (uk) 2002-06-17
NO955011L (no) 1995-12-11
HUT74266A (en) 1996-11-28
EP0703980A1 (fr) 1996-04-03
SK156895A3 (en) 1996-05-08
BR9407512A (pt) 1997-01-07
NZ268038A (en) 1997-12-19
JPH08511162A (ja) 1996-11-26
ATE231916T1 (de) 2003-02-15
CA2165458A1 (fr) 1994-12-22
EP0703980B1 (fr) 2003-01-29
FI956057A0 (fi) 1995-12-15
CA2165458C (fr) 2011-05-10
DE69432075D1 (de) 2003-03-06
CZ329595A3 (en) 1996-03-13
JP4384260B2 (ja) 2009-12-16
NO955011D0 (no) 1995-12-11
RU2218400C2 (ru) 2003-12-10
AU7076394A (en) 1995-01-03
CN1126491A (zh) 1996-07-10
KR100342233B1 (ko) 2002-12-05
FR2706486A1 (fr) 1994-12-23
FI956057A (fi) 1995-12-15
FR2706486B1 (fr) 1995-09-01
DK0703980T3 (da) 2003-05-19
CZ289039B6 (cs) 2001-10-17
ZA944303B (en) 1995-02-14
US6159947A (en) 2000-12-12
HU219138B (hu) 2001-02-28
CN1076052C (zh) 2001-12-12
DE69432075T2 (de) 2003-09-04
PL312213A1 (en) 1996-04-01
NO319466B1 (no) 2005-08-15
WO1994029446A2 (fr) 1994-12-22

Similar Documents

Publication Publication Date Title
ES2191031T3 (es) Proteinas intracelulares de enlace (pil) y sus utilizaciones.
ATE400651T1 (de) Verwendung von grünem fluoreszenzprotein
ATE348175T1 (de) Method eder intrazellularen bindung von zielgerichteten molekülen
FI934811A (fi) Stabiliserade enzymer och detergentfoereningar
WO1996039429A3 (en) Serum protein produced exclusively in adipocytes
DE60228212D1 (de) Neue expressionsvektoren
FI941947A (fi) Rekombinantti-core-streptavidiini
EP1517144A3 (en) Method of identifying an antibody binding to and modulating the activity of a human vanilloid receptor
TW272197B (es)
DE69637154D1 (de) Hocheffizientes gewebespezifisches system zur bereitstellung von verbindungen unter verwendung eines streptavidin-protein a fusionsproteins
ES2152313T3 (es) Gen grb-3-3, sus variantes y sus utilizaciones.
ATE274351T1 (de) Verwendung von isolierten domänen des type-iv- kollagens zur änderung der zell- und gewebewechselwirkung
MX9703475A (es) D-pantolactona hidrolasa y gen que codifica para la misma.
DK0773999T3 (da) OR-1, en orphan-receptor tilhørende kernereceptorfamilien
KR940008700A (ko) 사람형 모노클로날 항펩티드 항체 및 이것을 코드하는 dna
DK0788549T3 (da) Regulerende nukleinsyresekvenser og anvendelser
DE59611353D1 (de) Transketolase-verwandtes protein
MX9709459A (es) Metodo para prolongar la expresion de un gen de interes usando moleculas de ctla4 solubles.